Haylee N. Bernal Anderson

Haylee N. Bernal Anderson is a patent litigation attorney with Williams & Connolly, where she serves as Lead Counsel. Her practice appears to focus on high-stakes pharmaceutical patent disputes, particularly those involving biosimilars.

Anderson primarily represents plaintiffs, as evidenced by her role as Lead Counsel for Regeneron Pharmaceuticals, Inc. in its patent infringement case against Celltrion, Inc. This notable litigation centered on 38 patents protecting Regeneron's blockbuster anti-VEGF therapy EYLEA® (aflibercept), a pharmaceutical product.

The case, Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc., concluded on October 21, 2025, with a joint stipulation to dismiss all claims without prejudice. Public reports indicate this dismissal was part of a settlement that allows Celltrion to launch its EYLEA® biosimilar on December 31, 2026.

Details regarding Anderson's specific educational background, bar admissions, or extensive experience in PTAB/IPR proceedings are not readily available in publicly sourced information.